TEST:

Find It®

"This article underscores the importance of policies and practices that address the needs of disabled individuals and other marginalized populations, focusing on creating inclusive and effective screening systems. Recommendations are provided to guide future research, policy development, and clinical practices aimed at mitigating disparities in breast cancer screening."

We demonstrated the feasibility of obtaining actionable information within a clinically meaningful turnaround time using a robust NGS solution. For samples with sufficient tumour content and DNA for testing (>90% of samples), Find It had an approximately 99% success rate. Actionable information provided by the panel could impact clinical management for 66% of advanced-stage cancer patients.

Our targeted NGS panel has proved to be a cost-effective, robust solution, enabling the delivery of actionable information within a clinically meaningful turnaround time. For samples with sufficient neoplastic cell content and DNA quality for testing (>90% of samples), the test success rate with Find It of nearly 99% demonstrates that this targeted panel has met our high standards of molecular testing at Sonic Genetics.

ProMisE NGS is feasible on standard FFPE material, demonstrates high concordance with the original ProMisE classifier and maintains prognostic value in EC. This test has the potential to facilitate implementation of molecular classification of EC at the time of first diagnosis.

The one-step NGS molecular classifier demonstrates high concordance with the original ProMisE classifier including between biopsy and hysterectomy samples. This shows that reliable molecular testing could be obtained from time of first diagnosis. Prognostic value of this new one-step classification tool is maintained.

The MSI detection algorithm can accurately identify samples with MSI-H tumors. When used in a clinical setting, these patients can then be directed to treatments such as immune-checkpoint inhibitors.

Conclusions We demonstrate high concordance of a one step DNA-based EC molecular classifier when compared to the original ProMisE classifier, importantly maintaining the prognostic value of ProMisE and presenting an option for centers where routine MMR and p53 IHC are not performed. Further validation is needed before implementation into clinical practice.